Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B, Kamrul-Hasan A

Indian journal of endocrinology and metabolism4 Sept 2024Cited by 10 (Europe PMC)

PMID39676787PMCIDPMC11642503DOI10.4103/ijem.ijem_45_24PepBankPUB-39676787

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In obese individuals, CagriSema gave significantly greater percentage weight loss than semaglutide 2.4 mg in a meta-analysis of randomised trials.
In plain wordsIn people with obesity, CagriSema led to more percent weight loss than semaglutide alone in this pooled analysis of trials.
Peptide
Cagrilintide
Outcome
DecreasePercent body weight loss, CagriSema vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg weekly
Outcome group
Body weight · Metabolic and weight
Studied dose
cagrilintide 2.4 mg with semaglutide 2.4 mg · 20-32 weeksAs given in this study (human).
Measurements
Percentage weight loss mean difference
−9.07%
CagriSema vs semaglutide
Source sentences
Summary
At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23); P I ² = 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39); P I ² = 98%] weight-loss,…
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678701
02HumanSystematic reviewEfficacy outcome
In obese individuals, CagriSema gave significantly greater absolute weight loss than semaglutide 2.4 mg in a meta-analysis of randomised trials.
In plain wordsIn people with obesity, CagriSema led to more kilograms of weight loss than semaglutide alone in this pooled analysis of trials.
Peptide
Cagrilintide
Outcome
DecreaseAbsolute weight loss, CagriSema vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg weekly
Outcome group
Body weight · Metabolic and weight
Studied dose
cagrilintide 2.4 mg with semaglutide 2.4 mg · 20-32 weeksAs given in this study (human).
Measurements
Absolute weight loss mean difference
−9.11 kg
CagriSema vs semaglutide
Source sentences
Summary
At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23); P I ² = 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39); P I ² = 98%] weight-loss,…
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678702
03HumanSystematic reviewEfficacy outcome
In obese individuals, cagrilintide 2.4 mg gave similar percentage weight loss to semaglutide or liraglutide in a meta-analysis (P = 0.11).
In plain wordsIn people with obesity, cagrilintide gave about the same percent weight loss as semaglutide or liraglutide in this pooled analysis.
Peptide
Cagrilintide
Outcome
No significant changePercent body weight loss, cagrilintide vs semaglutide/liraglutide
Study
n: not reported in source
Comparator
Semaglutide or liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg · 26-32 weeksAs given in this study (human).
Measurements
Percentage weight loss mean difference
−1.83%
cagrilintide 2.4 mg vs semaglutide/liraglutide
Source sentences
Summary
At 26-32 weeks, cagrilintide 2.4 mg had a similar percentage [MD - 1.83% (95%CI: -4.08, -0.42); P = 0.11; I ² = 98%] and absolute [MD - 1.88 kg (95%CI: -4.23,0.47); P = 0.12; I ² = 98%] weight-loss, compared to semaglutide/liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678703
04HumanSystematic reviewEfficacy outcome
In obese individuals, cagrilintide 2.4 mg gave similar absolute weight loss to semaglutide or liraglutide in a meta-analysis (P = 0.12).
In plain wordsIn people with obesity, cagrilintide gave about the same kilograms of weight loss as semaglutide or liraglutide in this pooled analysis.
Peptide
Cagrilintide
Outcome
No significant changeAbsolute weight loss, cagrilintide vs semaglutide/liraglutide
Study
n: not reported in source
Comparator
Semaglutide or liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg · 26-32 weeksAs given in this study (human).
Measurements
Absolute weight loss mean difference
−1.88 kg
cagrilintide 2.4 mg vs semaglutide/liraglutide
Source sentences
Summary
At 26-32 weeks, cagrilintide 2.4 mg had a similar percentage [MD - 1.83% (95%CI: -4.08, -0.42); P = 0.11; I ² = 98%] and absolute [MD - 1.88 kg (95%CI: -4.23,0.47); P = 0.12; I ² = 98%] weight-loss, compared to semaglutide/liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678704
05HumanSystematic reviewSafety outcome
In obese individuals, gastrointestinal adverse events were significantly higher with CagriSema than with semaglutide in a meta-analysis.
In plain wordsIn people with obesity, CagriSema caused more stomach and gut side effects than semaglutide alone in this pooled analysis.
Peptide
Cagrilintide
Outcome
IncreaseGastrointestinal adverse events, CagriSema vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
cagrilintide 2.4 mg with semaglutide 2.4 mgAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678707
06HumanSystematic reviewSafety outcome
In obese individuals, vomiting was significantly higher with CagriSema than with semaglutide in a meta-analysis.
In plain wordsIn people with obesity, vomiting was more common with CagriSema than with semaglutide alone in this pooled analysis.
Peptide
Cagrilintide
Outcome
IncreaseVomiting, CagriSema vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
cagrilintide 2.4 mg with semaglutide 2.4 mgAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678708
07HumanSystematic reviewSafety outcome
In obese individuals, vomiting was significantly lower with cagrilintide than with semaglutide or liraglutide in a meta-analysis.
In plain wordsIn people with obesity, vomiting was less common with cagrilintide than with semaglutide or liraglutide in this pooled analysis.
Peptide
Cagrilintide
Outcome
DecreaseVomiting, cagrilintide vs semaglutide/liraglutide
Study
n: not reported in source
Comparator
Semaglutide or liraglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Vomiting was significantly lower with cagrilintide compared to semaglutide/liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
Report a problemFND-3967678709

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In obese adults, CagriSema (cagrilintide plus semaglutide) reduced body weight more than semaglutide 2.4 mg alone (mean difference -9.07%, -9.11 kg).
In plain wordsIn obese adults, a cagrilintide and semaglutide combination led to more weight loss than semaglutide alone in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseBody weight loss, CagriSema versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg weekly
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
weight loss mean difference
−9.07%
CagriSema vs semaglutide 2.4 mg
weight loss mean difference
−9.11 kg
CagriSema vs semaglutide 2.4 mg
Source sentences
Summary
At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23); P I ² = 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39); P I ² = 98%] weight-loss,…
1 context sentence(design, population, supporting numbers)
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3967678710
09HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In obese adults, gastrointestinal adverse events were significantly higher with CagriSema than with semaglutide alone.
In plain wordsIn obese adults, a cagrilintide and semaglutide combination caused more stomach and gut side effects than semaglutide alone.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events, CagriSema versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg weekly
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3967678711
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In obese adults, vomiting was significantly higher with CagriSema than with semaglutide alone.
In plain wordsIn obese adults, a cagrilintide and semaglutide combination caused more vomiting than semaglutide alone.
Peptide
Semaglutide
Outcome
IncreaseVomiting, CagriSema versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg weekly
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3967678712
11HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome
In obese individuals, treatment-emergent adverse events with cagrilintide or CagriSema were comparable between groups in a meta-analysis.
In plain wordsIn people with obesity, side effects that began during treatment were about equally common across the compared groups in this pooled analysis.
Peptide
Cagrilintide
Outcome
No significant changeTreatment-emergent adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Treatment-emergent and serious adverse events were comparable between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3967678705
12HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome
In obese individuals, serious adverse events with cagrilintide or CagriSema were comparable between groups in a meta-analysis.
In plain wordsIn people with obesity, serious side effects were about equally common across the compared groups in this pooled analysis.
Peptide
Cagrilintide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Treatment-emergent and serious adverse events were comparable between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator.
Summary · context
From 678 articles, data from 3 RCTs involving 430 individuals were analysed.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3967678706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:06 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:05 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Summary

Results from this study12

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

Keywords